Q-omics provides the consensus-scored SORD profile across patient tissues and cancer cell-line models. SORD expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SORD is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, SORD protein abundance shows 19,735 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, COAD, and PDAC as cancer lineages where SORD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SORD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SORD survival associations across molecular data types. SORD RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SORD RNA expression–survival associations across cancer types. High SORD expression shows unfavorable associations in UVM, MESO, ACC and LUAD, but favorable associations in KIRC and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SORD RNA expression.
This table summarizes SORD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SORD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SORD shows lower tumor expression in KIRP, THCA and KIRC and higher tumor expression in COAD, LUAD and LUSC. The COAD box plot shows higher SORD RNA expression in tumor versus normal tissue (log2 FC = +1.880, t-test p < 0.001).
This table shows molecular features associated with SORD in patient tissues and cancer cell lines. In patient samples, SORD shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SORD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SKIN.
